Literature DB >> 28945459

Importance of Pancreatic Enzyme Replacement Therapy after Surgery of Cancer of the Esophagus or the Esophagogastric Junction.

Thomas Kiefer1, Dorothea Krahl1, Kathrin Osthoff1, Peter Thuss-Patience2, Jörg Bunse3, Ulrich Adam4, Marc H Jansen5, Rudolf Ott6, Robert Pfitzmann7, Matthias Pross8, Thomas Kohlmann9, Georg Daeschlein10, Hermann Buhlert1, Heinz Völler1,11, Carsten Hirt12.   

Abstract

After surgical treatment of cancer of the esophagus or the esophagogastric junction we observed steatorrhea, which is so far seldom reported. We analyzed all patients treated in our rehabilitation clinic between 2011 and 2014 and focused on the impact of surgery on digestion of fat. Reported steatorrhea was anamnestic, no pancreatic function test was made. Here we show the results from 51 patients. Twenty-three (45%) of the patients reported steatorrhea. Assuming decreased pancreatic function pancreatic enzyme replacement therapy (PERT) was started or modified during the rehabilitation stay (in the following called STEA+). These patients were compared with the patients without steatorrhea and without PERT (STEA-). Maximum weight loss between surgery and rehabilitation start was 18 kg in STEA+ patient and 15.3 kg in STEA- patients. STEA+ patients gained more weight under PERT during the rehabilitation phase (3 wk) than STEA- patients without PERT (+1.0 kg vs. -0.3 kg, P = 0.032). We report for the first time, that patients after cancer related esophageal surgery show anamnestic signs of exocrine pancreas insufficiency and need PERT to gain body weight.

Entities:  

Mesh:

Year:  2017        PMID: 28945459     DOI: 10.1080/01635581.2017.1374419

Source DB:  PubMed          Journal:  Nutr Cancer        ISSN: 0163-5581            Impact factor:   2.900


  1 in total

1.  Influence of Treatment Caused Impairments on Anxiety and Depression in Patients with Cancer of the Esophagus or the Esophagogastric Junction.

Authors:  Thomas Kiefer; Dorothea Krahl; Carsten Hirt; Heinz Völler; Lorenz Völkel; Georg Daeschlein
Journal:  J Gastrointest Cancer       Date:  2020-03
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.